Satinderjit Locham1, Robert J Beaulieu2, Hanaa Dakour-Aridi1, Besma Nejim1, Mahmoud B Malas3,4,5. 1. Johns Hopkins Bayview Vascular and Endovascular Clinical Research Center, Baltimore, MD, USA. 2. Johns Hopkins Medical Institutions, Baltimore, MD, USA. 3. Johns Hopkins Bayview Vascular and Endovascular Clinical Research Center, Baltimore, MD, USA. bmalas1@jhmi.edu. 4. Center for Research Excellence and Clinical Trials, Johns Hopkins Hospital, Baltimore, MD, USA. bmalas1@jhmi.edu. 5. Johns Hopkins Medical Institutions, Baltimore, MD, USA. bmalas1@jhmi.edu.
Abstract
BACKGROUND: Antiplatelet therapy (APT) is often used on anecdotal grounds to improve vascular access patency. The aim of this study was to assess the role of APT in hemodialysis (HD) patients undergoing arteriovenous fistula (AVF) or graft (AVG) placement. METHODS: All patients in a large HD vascular qualitative initiative database (2011-2017) were included and divided into no antiplatelet therapy (no-APT) vs. any APT [aspirin (ASA) or P2Y12 inhibitors (PI)]. Multivariate [logistic (MLR) and Cox (MCR) regression] analyses were used as appropriate. RESULTS: A total of 24,847 patients undergoing HD access creation were identified (78% AVF). APT was noted among 49 and 46% of AVG and AVF patients, respectively. In MLR analysis, patients on no-APT vs. APT had a 12-fold increased risk of in-hospital mortality (odds ratio (OR) 11.79, [95% confidence interval 5.30-26.26]) and the risk of developing steal syndrome was higher among patients discharged on APT (OR 1.81, [1.19-2.76]). In patients undergoing AVF, primary patency (PP) was similar between APT and no-APT. However, in patients undergoing AVG, PP rates at 12 months were significantly higher for APT: ASA (47 vs. 41%) and PI (51 vs. 41%) than for no-APT (p = 0.008). At MCR analysis, the loss of PP at 12 months was 13% lower in ASA users (hazard ratio (HR) 0.87, [0.77-0.97], p = 0.02) and 24% lower in PI users (HR 0.76, [0.57-0.99], p = 0.046) compared to no-APT. CONCLUSION: In a large national database, we showed that antiplatelet therapy was associated with lower in-hospital mortality. Aspirin and P2Y12-inhibitor use among AVG patients demonstrated improved PP rates compared to no antiplatelet therapy. We recommend the use of antiplatelet therapy especially in patients on AVG.
BACKGROUND: Antiplatelet therapy (APT) is often used on anecdotal grounds to improve vascular access patency. The aim of this study was to assess the role of APT in hemodialysis (HD) patients undergoing arteriovenous fistula (AVF) or graft (AVG) placement. METHODS: All patients in a large HD vascular qualitative initiative database (2011-2017) were included and divided into no antiplatelet therapy (no-APT) vs. any APT [aspirin (ASA) or P2Y12 inhibitors (PI)]. Multivariate [logistic (MLR) and Cox (MCR) regression] analyses were used as appropriate. RESULTS: A total of 24,847 patients undergoing HD access creation were identified (78% AVF). APT was noted among 49 and 46% of AVG and AVF patients, respectively. In MLR analysis, patients on no-APT vs. APT had a 12-fold increased risk of in-hospital mortality (odds ratio (OR) 11.79, [95% confidence interval 5.30-26.26]) and the risk of developing steal syndrome was higher among patients discharged on APT (OR 1.81, [1.19-2.76]). In patients undergoing AVF, primary patency (PP) was similar between APT and no-APT. However, in patients undergoing AVG, PP rates at 12 months were significantly higher for APT: ASA (47 vs. 41%) and PI (51 vs. 41%) than for no-APT (p = 0.008). At MCR analysis, the loss of PP at 12 months was 13% lower in ASA users (hazard ratio (HR) 0.87, [0.77-0.97], p = 0.02) and 24% lower in PI users (HR 0.76, [0.57-0.99], p = 0.046) compared to no-APT. CONCLUSION: In a large national database, we showed that antiplatelet therapy was associated with lower in-hospital mortality. Aspirin and P2Y12-inhibitor use among AVG patients demonstrated improved PP rates compared to no antiplatelet therapy. We recommend the use of antiplatelet therapy especially in patients on AVG.
Authors: Albeir Y Mousa; William Patterson; Shadi Abu-Halimah; Stephen M Hass; Saadi Alhalbouni; Betro T Sadek; Aravinda Nanjundappa; Asmita Modak; Patrick A Stone; Mary Emmett; Ali F AbuRahma Journal: Vasc Endovascular Surg Date: 2013-07-12 Impact factor: 1.089
Authors: Mahmoud B Malas; Joseph K Canner; Caitlin W Hicks; Isibor J Arhuidese; Devin S Zarkowsky; Umair Qazi; Eric B Schneider; James H Black; Dorry L Segev; Julie A Freischlag Journal: JAMA Surg Date: 2015-05 Impact factor: 14.766
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Anton N Sidawy; Lawrence M Spergel; Anatole Besarab; Michael Allon; William C Jennings; Frank T Padberg; M Hassan Murad; Victor M Montori; Ann M O'Hare; Keith D Calligaro; Robyn A Macsata; Alan B Lumsden; Enrico Ascher Journal: J Vasc Surg Date: 2008-11 Impact factor: 4.268
Authors: Steven M Brunelli; Dena E Cohen; Gilbert Marlowe; Daniel Liu; Levi Njord; David Van Wyck; George Aronoff Journal: J Nephrol Date: 2019-01-02 Impact factor: 3.902